Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14242024 | 1.00 | CTSK (0.55) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL17870454 | 1.00 | CTSK (0.55) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL19003825 | 0.94 | CTSK (0.50) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL7426593 | 0.92 | CTSK (0.68) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL1433273 | 0.92 | CTSK (0.68) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL7424969 | 0.92 | CTSK (0.68) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL7425896 | 0.92 | CTSK (0.68) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL22412575 | 0.90 | CTSK (0.50) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL22412574 | 0.90 | CTSK (0.50) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL22412573 | 0.90 | CTSK (0.50) | CTSKCTSSPPARAPPARGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180265547-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-09-20 | — | — | US | disclosed |
| US-20160185821-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185821-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | QPCT, PTMS, MAX | CTSK 194/4885CTSS 203/4885PPARA 2535/4885 |
| US-20180265547-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | QPCT, PTMS, MAX | CTSK 194/4885CTSS 203/4885PPARA 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.